Drug Trial Radar · NCT05714891
Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
4
Actual
Start
Sep 15, 2023
Primary completion
Dec 31, 2026
Study completion Mar 31, 2028
Sponsor
- Lead sponsor
- Canadian Cancer Trials GroupResearch network
- Sponsor type
- Research network
- Collaborators
- Novartis
- First posted
- Feb 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being done to answer the following question: What are the effects of new treatments on non-small cell lung cancer before surgery?
Conditions
- NSCLC
Interventions
JDQ443Drug
Dose will be assigned at enrollment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Identify promising neoadjuvant treatment regimens for NSCLC for later validation in randomized clinical trials, by evaluating major pathological response rates (MPR)Time frame: 3 years
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
CancerCare Manitoba
Winnipeg, Manitoba, Canada
Kingston Health Sciences Centre
Kingston, Ontario, Canada
London Health Sciences Centre Research Inc.
London, Ontario, Canada
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
University Health Network
Toronto, Ontario, Canada
CHUM-Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, Canada
The Research Institute of the McGill University
Montreal, Quebec, Canada
University Institute of Cardiology and
Québec, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.